Carbapenem-resistant Gram-negative bacteria: How to prioritize infection prevention and control interventions in resource-limited settings?

Expert Review of Anti-Infective Therapy

Volumn 11, Issue 2, 2013, Pages 147-157

  Apisarnthanarak, Anucha ^a   Hsu, Li Yang ^b   Khawcharoenporn, Thana ^a   Mundy, Linda M ^c  

^a THAMMASAT UNIVERSITY   (Thailand)

^b NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^c GLAXOSMITHKLINE   (United States)

Author keywords

epidemiology; Escherichia coli; Gram negative; infection prevention; Klebsiella pneumoniae; Pseudomonas aeruginosa; resource limited settings

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOPENICILLIN; CARBAPENEM; CARBAPENEMASE; CEPHALOSPORIN DERIVATIVE; GLYCOPEPTIDE; KLEBSIELLA PNEUMONIAE CARBAPENEMASE; METALLO BETA LACTAMASE; METRONIDAZOLE; NEW DELHI METALLO BETA LACTAMASE 1; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG; VANCOMYCIN;

ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; ARTICLE; AWARENESS; BACTERIAL COLONIZATION; BACTERIAL TRANSMISSION; CARBAPENEM RESISTANT ACINETOBACTER BAUMANNII; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CARBAPENEM RESISTANT GRAM NEGATIVE BACTERIUM; CARBAPENEM RESISTANT PSEUDOMONAS AERUGINOSA; CARBAPENEMASE GENE; CLEANING; CONTACT ISOLATION; DISEASE SURVEILLANCE; DRUG USE; ENTEROBACTERIACEAE INFECTION; EVIDENCE BASED PRACTICE; GENE; GRAM NEGATIVE BACTERIUM; HAND WASHING; HEALTH PERSONNEL ATTITUDE; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; MOLECULAR EPIDEMIOLOGY; NONHUMAN; PATIENT CARE; PATIENT COMPLIANCE; PSEUDOMONAS INFECTION; RISK FACTOR;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; CARBAPENEMS; COMMUNICABLE DISEASE CONTROL; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INCIDENCE; PSEUDOMONAS AERUGINOSA;

EID: 84873883973     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.12.164     Document Type: Article

References (121)

1. Kattan JN, Villegas MV, Quinn JP. New developments in carbapenems. Clin. Microbiol. Infect. 14(12), 1102-1111 (2008).
2. Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin. Infect. Dis. 53(1), 60-67 (2011).
3. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48(1), 1-12 (2009).
4. Mouloudi E, Protonotariou E, Zagorianou A et al. Bloodstream infections caused by metallo-b-lactamase/Klebsiella pneumoniae carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes. Infect. Control Hosp. Epidemiol. 31(12), 1250-1256 (2010).
5. Lautenbach E, Weiner MG, Nachamkin I, Bilker WB, Sheridan A, Fishman NO. Imipenem resistance among Pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infect. Control Hosp. Epidemiol. 27(9), 893-900 (2006).
6. Sheng WH, Liao CH, Lauderdale TL et al. A multicenter study of risk factors and outcome of hospitalized patients with infections due to carbapenem-resistant Acinetobacter baumannii. Int. J. Infect. Dis. 14(9), e764-e769 (2010).
7. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect. Control Hosp. Epidemiol. 29(12), 1099-1106 (2008).
8. Schwaber MJ, Klarfeld-Lidji S, Navon- Venezia S, Schwartz D, Leavitt A, Carmeli Y. Predictors of carbapenemresistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob. Agents Chemother. 52(3), 1028-1033 (2008).
9. Rodriguez-Martinez JM, Poirel L, Nordmann P. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53(11), 4783-4788 (2009).
10. Pournaras S, Maniati M, Petinaki E et al. Hospital outbreak of multiple clones of Pseudomonas aeruginosa carrying the unrelated metallo-?-lactamase gene variants blaVIM-2 and blaVIM-4. J. Antimicrob. Chemother. 51(6), 1409-1414 (2003).
11. Gibb AP, Tribuddharat C, Moore RA et al. Nosocomial outbreak of carbapenem-resistant Pseudomonas aeruginosa with a new bla(IMP) allele, bla(IMP-7).
12. Antimicrob. Agents Chemother 46 1 255-258 (2002).
13. Kim YJ, Kim SI, Kim YR et al. Carbapenem- resistant Acinetobacter baumannii: diversity of resistant mechanisms and risk factors for infection. Epidemiol. Infect. 140(1), 137-145 (2012).
14. Kumarasamy KK, Toleman MA, Walsh TR et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect. Dis. 10(9), 597-602 (2010).
15. Mataseje LF, Bryce E, Roscoe D et al.; Canadian Nosocomial Infection Surveillance Program. Carbapenem-resistant Gram-negative bacilli in Canada 2009-10: results from the Canadian Nosocomial Infection Surveillance Program (CNISP). J. Antimicrob. Chemother. 67(6), 1359-1367 (2012).
16. Vatopoulos A. High rates of metallo-?- lactamase-producing Klebsiella pneumoniae in Greece - a review of the current evidence. Euro. Surveill. 13, 8023 (2008).
17. Leavitt A, Navon-Venezia S, Chmelnitsky I, Schwaber MJ, Carmeli Y. Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. Antimicrob. Agents Chemother. 51(8), 3026-3029 (2007).
18. El-Herte RI, Kanj SS, Matar GM, Araj GF. The threat of carbapenem-resistant Enterobacteriaceae in Lebanon: an update on the regional and local epidemiology. J. Infect. Public Health 5(3), 233-243 (2012).
19. Hidron AI, Edwards JR, Patel J et al.; National Healthcare Safety Network Team; Participating National Healthcare Safety Network Facilities. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect. Control Hosp. Epidemiol. 29(11), 996-1011 (2008).
20. Rhomberg PR, Jones RN. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008). Diagn. Microbiol. Infect. Dis. 65(4), 414-426 (2009).
21. Bratu S, Landman D, Haag R et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch. Intern. Med. 165(12), 1430-1435 (2005).
22. Yigit H, Queenan AM, Anderson GJ et al. Novel carbapenem-hydrolyzing ?-lactamase, KPC-1, from a carbapenemresistant strain of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 45(4), 1151-1161 (2001).
23. Yong D, Toleman MA, Giske CG et al. Characterization of a new metallo-?- lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob. Agents Chemother. 53(12), 5046-5054 (2009).
24. Struelens MJ, Monnet DL, Magiorakos AP, Santos O'Connor F, Giesecke J. New Delhi metallo-?-lactamase 1-producing Enterobacteriaceae: emergence and response in Europe. Euro. Surveill. 15(46), 19716 (2010).
25. Maltezou HC, Giakkoupi P, Maragos A et al. Outbreak of infections due to KPC-2-producing Klebsiella pneumoniae in a hospital in Crete (Greece). J. Infect. 58(3), 213-219 (2009).
26. Gregory CJ, Llata E, Stine N et al. Outbreak of carbapenem-resistant Klebsiella pneumoniae in Puerto Rico associated with a novel carbapenemase variant. Infect. Control Hosp. Epidemiol. 31(5), 476-484 (2010).
27. Jeon MH, Choi SH, Kwak YG et al. Risk factors for the acquisition of carbapenemresistant Escherichia coli among hospitalized patients. Diagn. Microbiol. Infect. Dis. 62(4), 402-406 (2008).
28. Hussein K, Sprecher H, Mashiach T, Oren I, Kassis I, Finkelstein R. Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns. Infect. Control Hosp. Epidemiol. 30(7), 666-671 (2009).
29. Wu D, Cai J, Liu J. Risk factors for the acquisition of nosocomial infection with carbapenem-resistant Klebsiella pneumoniae. South. Med. J. 104(2), 106-110 (2011).
30. Wiener-Well Y, Rudensky B, Yinnon AM et al. Carriage rate of carbapenem-resistant Klebsiella pneumoniae in hospitalised patients during a national outbreak. J. Hosp. Infect. 74(4), 344-349 (2010).
31. Savard P, Perl TM. A call for action: managing the emergence of multidrugresistant Enterobacteriaceae in the acute care settings. Curr. Opin. Infect. Dis. 25(4), 371-377 (2012).
32. Williamson DA, Sidjabat HE, Freeman JT et al. Identification and molecular characterisation of New Delhi metallob- lactamase-1 (NDM-1)- and NDM- 6-producing Enterobacteriaceae from New Zealand hospitals. Int. J. Antimicrob. Agents 39(6), 529-533 (2012).
33. Behera B, Das A, Mathur P, Kapil A. High prevalence of carbapenem resistant Pseudomonas aeruginosa at a tertiary care centre of north India. Are we under-reporting? Indian J. Med. Res. 128(3), 324-325 (2008).
34. Lee JY, Ko KS. OprD mutations and inactivation, expression of efflux pumps and AmpC, and metallo-?-lactamases in carbapenem-resistant Pseudomonas aeruginosa isolates from South Korea. Int. J. Antimicrob. Agents 40(2), 168-172 2012.
35. Onguru P, Erbay A, Bodur H et al. Imipenem-resistant Pseudomonas aeruginosa: risk factors for nosocomial infections. J. Korean Med. Sci. 23(6), 982-987 (2008).
36. Dejsirilert S, Suankratay C, Trakulsomboon S et al. National Antimicrobial Resistance Surveillance, Thailand (NARST) data among clinical isolates of Pseudomonas aeruginosa in Thailand from 2000 to 2005. J. Med. Assoc. Thai. 92(Suppl. 4), S68-S75 (2009).
37. Baumgart AM, Molinari MA, Silveira AC. Prevalence of carbapenem resistant Pseudomonas aeruginosa and Acinetobacter baumannii in high complexity hospital. Braz. J. Infect. Dis. 14(5), 433-436 (2010).
38. Laupland KB, Parkins MD, Church DL et al. Population-based epidemiological study of infections caused by carbapenemresistant Pseudomonas aeruginosa in the Calgary Health Region: importance of metallo-?-lactamase (MBL)-producing strains. J. Infect. Dis. 192(9), 1606-1612 (2005).
39. Lagatolla C, Tonin EA, Monti-Bragadin C et al. Endemic carbapenem-resistant Pseudomonas aeruginosa with acquired metallo-?-lactamase determinants in European hospital. Emerging Infect. Dis. 10(3), 535-538 (2004).
40. Wolter DJ, Khalaf N, Robledo IE et al. Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 ?-lactamases. Antimicrob. Agents Chemother. 53(4), 1660-1664 (2009).
41. Rhomberg PR, Deshpande LM, Kirby JT, Jones RN. Activity of meropenem as serine carbapenemases evolve in US Medical Centers: monitoring report from the MYSTIC Program (2006). Diagn. Microbiol. Infect. Dis. 59(4), 425-432 (2007).
42. Harris AD, Smith D, Johnson JA, Bradham DD, Roghmann MC. Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients. Clin. Infect. Dis. 34(3), 340-345 (2002).
43. Furtado GH, Gales AC, Perdiz LB, Santos AE, Wey SB, Medeiros EA. Risk factors for hospital-acquired pneumonia caused by imipenem-resistant Pseudomonas aeruginosa in an intensive care unit. Anaesth. Intensive Care 38(6), 994-1001 (2010).
44. Furtado GH, Bergamasco MD, Menezes FG et al. Imipenem-resistant Pseudomonas aeruginosa infection at a medical-surgical intensive care unit: risk factors and mortality. J. Crit. Care 24(4), 625.e9-625.e14 (2009).
45. Pena C, Suarez C, Tubau F et al. Carbapenem- resistant Pseudomonas aeruginosa: factors influencing multidrug-resistant acquisition in non-critically ill patients. Eur. J. Clin. Microbiol. Infect. Dis. 28(5), 519-522 (2009).
46. Ozkurt Z, Ertek M, Erol S, Altoparlak U, Akcay MN. The risk factors for acquisition of imipenem-resistant Pseudomonas aeruginosa in the burn unit. Burns 31(7), 870-873 (2005).
47. Gaynes RP, Culver DH. Resistance to imipenem among selected Gram-negative bacilli in the United States. Infect. Control Hosp. Epidemiol. 13(1), 10-14 (1992).
48. Gulay Z, Atay T, Amyes SG. Clonal spread of imipenem-resistant Pseudomonas aeruginosa in the intensive care unit of a Turkish hospital. J. Chemother. 13(5), 546-554 (2001).
49. Zavascki AP, Cruz RP, Goldani LZ. Risk factors for imipenem-resistant Pseudomonas aeruginosa: a comparative analysis of two case-control studies in hospitalized patients. J. Hosp. Infect. 59(2), 96-101 (2005).
50. Shigemi A, Matsumoto K, Yaji K et al. Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa. Int. J. Antimicrob. Agents 34(6), 589-591 (2009).
51. Carmeli Y, Lidji SK, Shabtai E, Navon- Venezia S, Schwaber MJ. The effects of group 1 versus group 2 carbapenems on imipenem-resistant Pseudomonas aeruginosa: an ecological study. Diagn. Microbiol. Infect. Dis. 70(3), 367-372 (2011).
52. Troillet N, Samore MH, Carmeli Y. Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns. Clin. Infect. Dis. 25(5), 1094-1098 (1997).
53. Kohlenberg A, Weitzel-Kage D, van der Linden P et al. Outbreak of carbapenem-resistant Pseudomonas aeruginosa infection in a surgical intensive care unit. J. Hosp. Infect. 74(4), 350-357 (2010).
54. Ying CM, Ling TK, Lee CC, Ling JM. Characterization of carbapenem-resistant Acinetobacter baumannii in Shanghai and Hong Kong. J. Med. Microbiol. 55(Pt 6), 799-802 (2006).
55. Routsi C, Pratikaki M, Platsouka E et al. Carbapenem-resistant versus carbapenemsusceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes. Infection 38(3), 173-180 (2010).
56. Le Hello S, Falcot V, Lacassin F, Mikulski M, Baumann F. Risk factors for carbapenem- resistant Acinetobacter baumannii infections at a tertiary care hospital in New Caledonia, South Pacific. Scand. J. Infect. Dis. 42(11-12), 821-826 (2010).
57. Asensio A, Canton R, Vaque J et al. Prevalence of infection by carbapenemresistant Acinetobacter baumannii in Spain (1999-2005).
58. Enferm. Infecc. Microbiol. Clin 26 4 199-204 2008
59. Peleg AY, Franklin C, Bell JM, Spelman DW. Emergence of carbapenem resistance in Acinetobacter baumannii recovered from blood cultures in Australia. Infect. Control Hosp. Epidemiol. 27(7), 759-761 (2006).
60. Dejsirilert S, Tiengrim S, Sawanpanyalert P, Aswapokee N, Malathum K. Antimicrobial resistance of Acinetobacter baumannii: six years of National Antimicrobial Resistance Surveillance Thailand (NARST) surveillance. J. Med. Assoc. Thai. 92(Suppl. 4), S34-S45 (2009).
61. Su CH, Wang JT, Hsiung CA et al. Increase of carbapenem-resistant Acinetobacter baumannii infection in acute care hospitals in Taiwan: association with hospital antimicrobial usage. PLoS ONE 7(5), e37788 (2012).
62. Akinci E, Colpan A, Bodur H, Balaban N, Erbay A. Risk factors for ICU-acquired imipenem-resistant Gram-negative bacterial infections. J. Hosp. Infect. 59(4), 317-323 (2005).
63. Cisneros JM, Rodriguez-Bano J, Fernandez- Cuenca F et al.; Spanish Group for Nosocomial Infection (GEIH) for the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). Riskfactors for the acquisition of imipenemresistant Acinetobacter baumannii in Spain: a nationwide study. Clin. Microbiol. Infect. 11(11), 874-879 (2005).
64. Playford EG, Craig JC, Iredell JR. Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: risk factors for acquisition, infection and their consequences. J. Hosp. Infect. 65(3), 204-211 (2007).
65. Aydemir H, Celebi G, Piskin N et al. Mortality attributable to carbapenemresistant nosocomial Acinetobacter baumannii infections in a Turkish university hospital. Jpn J. Infect. Dis. 65(1), 66-71 (2012).
66. Shah PM, Isaacs RD. Ertapenem, the first of a new group of carbapenems. J. Antimicrob. Chemother. 52(4), 538-542 (2003).
67. Doumith M, Ellington MJ, Livermore DM, Woodford N. Molecular mechanisms disrupting porin expression in ertapenemresistant Klebsiella and Enterobacter spp. clinical isolates from the UK. J. Antimicrob. Chemother. 63(4), 659-667 (2009).
68. Walsh TR. Emerging carbapenemases: a global perspective. Int. J. Antimicrob. Agents 36(Suppl. 3), S8-S14 (2010).
69. Pfeifer Y, Cullik A, Witte W. Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens. Int. J. Med. Microbiol. 300(6), 371-379 (2010).
70. Mart?nez-Mart?nez L, Pascual A, Hern?ndez-All?s S et al. Roles of ?-lactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae. Antimicrob. Agents Chemother. 43(7), 1669-1673 (1999).
71. Canton R, Akova M, Carmeli Y et al.; European Network on Carbapenemases. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin. Microbiol. Infect. 18(5), 413-431 (2012).
72. Poirel L, Potron A, Nordmann P. OXA-48-like carbapenemases: the phantom menace. J. Antimicrob. Chemother. 67(7), 1597-1606 (2012).
73. Wilson ME, Chen LH. NDM-1 and the role of travel in its dissemination. Curr. Infect. Dis. Rep. 14(3), 213-226 (2012).
74. Kitchel B, Rasheed JK, Patel JB et al. Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258. Antimicrob. Agents Chemother. 53(8), 3365-3370 (2009).
75. Carrer A, Poirel L, Yilmaz M, Akan OA, Feriha C, Cuzon G. Emerging spread of OXA-48-encoding plasmid from Turkey and beyond. Antimicrob. Agents Chemother. 54, 1369-1373 (2010).
76. Nordmann P, Poirel L, Walsh TR, Livermore DM. The emerging NDM carbapenemases. Trends Microbiol. 19(12), 588-595 (2011).
77. McGowan JE Jr. Resistance in nonfermenting Gram-negative bacteria: multidrug resistance to the maximum. Am. J. Infect. Control 34(5 Suppl. 1), S29-S37; discussion S64 (2006).
78. Coyne S, Courvalin P, Perichon B. Efflux-mediated antibiotic resistance in Acinetobacter spp. Antimicrob. Agents Chemother. 55(3), 947-953 (2011).
79. Alvarez-Ortega C, Wiegand I, Olivares J, Hancock RE, Martinez JL. The intrinsic resistome of Pseudomonas aeruginosa to b-lactams. Virulence 2(2), 144-146 (2011).
80. Catel-Ferreira M, Coadou G, Molle V et al. Structure-function relationships of CarO, the carbapenem resistance-associated outer membrane protein of Acinetobacter baumannii. J. Antimicrob. Chemother. 66(9), 2053-2056 (2011).
81. Liu YM, Chen YS, Toh HS et al. In vitro susceptibilities of non-Enterobacteriaceae isolates from patients with intra-abdominal infections in the Asia-Pacific region from 2003 to 2010: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART). Int. J. Antimicrob. Agents 40(Suppl.), S11-S17 (2012).
82. Siarkou VI, Vitti D, Protonotariou E, Ikonomidis A, Sofianou D. Molecular epidemiology of outbreak-related Pseudomonas aeruginosa strains carrying the novel variant blaVIM-17 metallo-?- lactamase gene. Antimicrob. Agents Chemother. 53(4), 1325-1330 (2009).
83. Koh TH, Khoo CT, Tan TT et al. Multilocus sequence types of carbapenemresistant Pseudomonas aeruginosa in Singapore carrying metallo-?-lactamase genes, including the novel bla(IMP-26) gene. J. Clin. Microbiol. 48(7), 2563-2564 (2010).
84. Garcia-Castillo M, Del Campo R, Morosini MI et al. Wide dispersion of ST175 clone despite high genetic diversity of carbapenem-nonsusceptible Pseudomonas aeruginosa clinical strains in 16 Spanish hospitals. J. Clin. Microbiol. 49(8), 2905-2910 (2011).
85. Durante-Mangoni E, Zarrilli R. Global spread of drug-resistant Acinetobacter baumannii: molecular epidemiology and management of antimicrobial resistance. Future Microbiol. 6(4), 407-422 (2011).
86. Woodford N, Turton JF, Livermore DM. Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol. Rev. 35(5), 736-755 (2011).
87. Poirel L, Nordmann P, Lagrutta E, Cleary T, Munoz-Price LS. Emergence of KPC-producing Pseudomonas aeruginosa in the United States. Antimicrob. Agents Chemother. 54, 3072 (2010).
88. Robledo IE, Aquino EE, Vazquez GJ. Detection of the KPC gene in Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii during a PCR-based nosocomial surveillance study in Puerto Rico. Antimicrob. Agents Chemother. 55(6), 2968-2970 (2011).
89. Harris AD, McGregor JC, Furuno JP. What infection control interventions should be undertaken to control multidrugresistant Gram-negative bacteria? Clin. Infect. Dis. 43(Suppl. 2), S57-S61 (2006).
90. Nicolau DP, Carmeli Y, Crank CW et al. Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence. Int. J. Antimicrob. Agents 39(1), 11-15 (2012).
91. Tam VH, Hirsch EB, Lasco TM, Gentry LO, Palmer HR. Correlation of hospital carbapenem consumption and resistance trends in selected Gram-negative bacteria. Ann. Pharmacother. 46(7-8), 1120-1122 (2012).
92. Borer A, Eskira S, Nativ R et al. A multifaceted intervention strategy for eradication of a hospital-wide outbreak caused by carbapenem-resistant Klebsiella pneumoniae in Southern Israel. Infect. Control Hosp. Epidemiol. 32(12), 1158-1165 (2011).
93. Ciobotaro P, Oved M, Nadir E, Bardenstein R, Zimhony O. An effective intervention to limit the spread of an epidemic carbapenem-resistant Klebsiella pneumoniae strain in an acute care setting: from theory to practice. Am. J. Infect. Control 39(8), 671-677 (2011).
94. Cohen MJ, Block C, Levin PD et al. Institutional control measures to curtail the epidemic spread of carbapenem-resistant Klebsiella pneumoniae: a 4-year perspective. Infect. Control Hosp. Epidemiol. 32(7), 673-678 (2011).
95. Schwaber MJ, Lev B, Israeli A et al.; Israel Carbapenem-Resistant Enterobacteriaceae Working Group. Containment of a country-wide outbreak of carbapenemresistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin. Infect. Dis. 52(7), 848-855 (2011).
96. Ben-David D, Masarwa S, Navon-Venezia S et al.; Israel PACF CRKP (Post-Acute- Care Facility Carbapenem-Resistant Klebsiella pneumoniae) Working Group. Carbapenem-resistant Klebsiella pneumoniae in post-acute-care facilities in Israel. Infect. Control Hosp. Epidemiol. 32(9), 845-853 (2011).
97. Kochar S, Sheard T, Sharma R et al. Success of an infection control program to reduce the spread of carbapenem-resistant Klebsiella pneumoniae. Infect. Control Hosp. Epidemiol. 30(5), 447-452 (2009).
98. Poulou A, Voulgari E, Vrioni G et al. Imported Klebsiella pneumoniae carbapenemase- producing K. pneumoniae clones in a Greek hospital: impact of infection control measures for restraining their dissemination. J. Clin. Microbiol. 50(8), 2618-2623 (2012).
99. Agodi A, Voulgari E, Barchitta M et al. Containment of an outbreak of KPC-3-producing Klebsiella pneumoniae in Italy. J. Clin. Microbiol. 49(11), 3986-3989 (2011).
100. Carbonne A, Thiolet JM, Fournier S et al. Control of a multi-hospital outbreak of KPC-producing Klebsiella pneumoniae type 2 in France, September to October 2009. Euro Surveill. 15(48), 19734 (2010).
101. Das I, Lambert P, Hill D, Noy M, Bion J, Elliott T. Carbapenem-resistant Acinetobacter and role of curtains in an outbreak in intensive care units. J. Hosp. Infect. 50(2), 110-114 (2002).
102. Fierobe L, Lucet JC, Decre D et al. An outbreak of imipenem-resistant Acinetobacter baumannii in critically ill surgical patients. Infect. Control Hosp. Epidemiol. 22(1), 35-40 (2001).
103. Doidge M, Allworth AM, Woods M et al. Control of an outbreak of carbapenemresistant Acinetobacter baumannii in Australia after introduction of environmental cleaning with a commercial oxidizing disinfectant. Infect. Control Hosp. Epidemiol. 31(4), 418-420 (2010).
104. Aygun G, Demirkiran O, Utku T et al. Environmental contamination during a carbapenem-resistant Acinetobacter baumannii outbreak in an intensive care unit. J. Hosp. Infect. 52(4), 259-262 (2002).
105. Apisarnthanarak A, Pinitchai U, Thongphubeth K, Yuekyen C, Warren DK, Fraser VJ; Thammasat University Pandrug-Resistant Acinetobacter baumannii Control Group. A multifaceted intervention to reduce pandrug-resistant Acinetobacter baumannii colonization and infection in 3 intensive care units in a Thai tertiary care center: a 3-year study. Clin. Infect. Dis. 47(6), 760-767 (2008).
106. Apisarnthanarak A, Warren DK, Fraser VJ. Creating a cohort area to limit transmission of pandrug-resistant Acinetobacter baumannii in a Thai tertiary care center. Clin. Infect. Dis. 48(10), 1487-1488 (2009).
107. Thatrimontrichai A, Apisarnthanarak A, Chanvitan P, Janjindamai W, Dissaneevate S, Maneenil G. Risk factors and outcomes of carbapenem-resistant Acinetobacter baumannii bacteremia in neonatal intensive care unit: a case-case-control study. Pediatr. Infect. Dis. J. doi:10.1097/ INF.0b013e318270b108 (2012) (Epub ahead of print).
108. Chitnis AS, Caruthers PS, Rao AK et al. Outbreak of carbapenem-resistant enterobacteriaceae at a long-term acute care hospital: sustained reductions in transmission through active surveillance and targeted interventions. Infect. Control Hosp. Epidemiol. 33(10), 984-992 (2012).
109. Tsakris A, Poulou A, Pournaras S et al. A simple phenotypic method for the differentiation of metallo-?-lactamases and class A KPC carbapenemases in Enterobacteriaceae clinical isolates. J. Antimicrob. Chemother. 65(8), 1664-1671 (2010).
110. Pournaras S, Poulou A, Tsakris A. Inhibitor-based methods for the detection of KPC carbapenemase-producing Enterobacteriaceae in clinical practice by using boronic acid compounds. J. Antimicrob. Chemother. 65(7), 1319-1321 (2010).
111. Adler A, Navon-Venezia S, Moran-Gilad J, Marcos E, Schwartz D, Carmeli Y. Laboratory and clinical evaluation of screening agar plates for detection of carbapenem-resistant Enterobacteriaceae from surveillance rectal swabs. J. Clin. Microbiol. 49(6), 2239-2242 (2011).
112. Spellberg B, Guidos R, Gilbert D et al.; Infectious Diseases Society of America. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin. Infect. Dis. 46(2), 155-164 (2008).
113. Siegel JD, Rhinehart E, Jackson M, Chiarello L; Healthcare Infection Control Practices Advisory Committee. Management of multidrug-resistant organisms in health care settings, 2006. Am. J. Infect. Control 35(10 Suppl 2), S165-S193 (2007).
114. CDC. Guidance for control of infections with carbapenem-resistant or carbapenemase- producing Enterobacteriaceae in acute care facilities. MMWR Morb. Mortal. Wkly Rep. 58(10), 256-260 (2009).
115. Bilavsky E, Schwaber MJ, Carmeli Y. How to stem the tide of carbapenemase-producing enterobacteriaceae?: Proactive versus reactive strategies. Curr. Opin. Infect. Dis. 23(4), 327-331 (2010).
116. Tsakris A, Kristo I, Poulou A et al. Evaluation of boronic acid disk tests for differentiating KPC-possessing Klebsiella pneumoniae isolates in the clinical laboratory. J. Clin. Microbiol. 47(2), 362-367 (2009).
117. Apisarnthanarak A, Kiratisin P, Khawcharoenporn T, Warren DK. Using an intensified infection prevention intervention to control carbapenemaseproducing Enterobacteriaceae at a Thai center. Infect. Control Hosp. Epidemiol. 33(9), 960-961 (2012).
118. Wenzel RP. Minimizing surgical-site infections. N. Engl. J. Med. 362(1), 75-77 (2010).
119. Apisarnthanarak A, Khawcharoenporn T, Mundy LM. Practices to prevent multidrugresistant Acinetobacter baumannii and methicillin-resistant Staphylococcus aureus in Thailand: a national survey. Am. J. Infect. Control doi:10.1016/j.ajic.2012.05.011 (2012) (Epub ahead of print).
120. Apisarnthanarak A, Fraser VJ. Feasibility and efficacy of infection-control interventions to reduce the number of nosocomial infections and drug-resistant microorganisms in developing countries: what else do we need? Clin. Infect. Dis. 48(1), 22-24 (2009).
121. Snitkin ES, Zelazny AM, Thomas PJ et al.; NISC Comparative Sequencing Program Group. Tracking a hospital outbreak of carbapenem-resistant Klebsiella pneumoniae with whole-genome sequencing. Sci. Transl. Med. 4(148), 148ra116 (2012).